



## Announcement

10.04.2012

### Report on Annual General Meeting held in NeuroSearch A/S

At the company's Annual General Meeting today, the following decisions were taken by the general meeting:

- The 2011 Annual Report and the Board of Director's proposal regarding the transfer of profits and losses for 2011 to next year were adopted.
- The Board of Directors was re-elected and thus still consists of Thomas Hofman-Bang (Chairman), Allan Andersen, Torbjörn Bjerke, Anders Ullman, Ian Talmage and the following newly elected employee representatives: Carsten Jessen, Janus Schreiber Larsen and Lars Siim Madsen.
- PricewaterhouseCoopers was re-elected as the company's auditor.
- The Board withdrew its proposal regarding the possibility of using electronic communication between the company and its shareholders.
- The Board's proposed change to the remuneration policy for the Board of Directors and Executive Management was adopted.
- The proposed fee to the Board of Directors for 2012 was approved.
- The general meeting authorised the Board to purchase own shares of up to a total nominal value of DKK 2,455,394 (corresponding to 10% of the company's present share capital) in the period until the next Annual General Meeting.

Patrik Dahlen  
CEO

#### Contact persons:

Patrik Dahlen, CEO, telephone: +45 2629 7296  
René Schneider, EVP & CFO, telephone: +45 2911 2097

#### About NeuroSearch

NeuroSearch is a European-based biopharmaceutical company specialising in CNS diseases. The company is listed on NASDAQ OMX Copenhagen A/S. The company's product pipeline comprises Huntexil® for the treatment of motor symptoms in patients with Huntington's disease and orodopidine and seridopidine, which have both completed Phase I development. Huntexil® is currently in Phase III development. The overall objective for NeuroSearch is to create a profitable, specialty pharma company building on the platform the company will achieve from a successful development and marketing of Huntexil®. The company also has a portfolio of assets for outlicensing or divestment.

